Search

Your search keyword '"Güralp Taşan"' showing total 3 results
Start Over Author "Güralp Taşan"
3 results on '"Güralp Taşan"'

1. The Correlation between New Serological Markers and Disease Phenotype and Activation in Inflammatory Bowel Disease

Author

Elif Yorulmaz, Gupse Adalı, Hatice Yorulmaz, Güralp Taşan, Seval Gürses, Mehmet Ramazan Ayaş, and İlyas Tuncer

Subjects
Hepatology, Gastroenterology
Abstract

Background: The aim of the study is to assess the correlation between a new antibody panel that is developed against glycans on Crohn’s disease (CD) and ulcerative colitis (UC) differentiative diagnosis and disease properties. Methods: In the study, 137 CD and 122 UC patients and 90 controls were included. Anti-saccharomyces cerevisiae IgG (ASCA), anti-laminaribioside IgG (ALCA), anti-chitobioside IgA (ACCA), and anti-mannobioside IgG (AMCA) were tested in serum. Results: While at least 1 of the other 3 serological markers was positive in 89% of ASCA-positive patients, at least 1 of the other 3 serological markers was positive in 77% of ASCA-negative patients. Positivity ratio for a single anticarbohydrate was ALCA 18 (22%), ACCA 5 (12%), and AMCA 16 (23%). A significant correlation was found between ASCA positivity (P

Published
2021

2. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients

Author

Sabahattin Kaymakoglu, Ahmet Bektaş, Güralp Taşan, Yusuf Erzin, Sule Poturoglu, Ozan Kocakaya, Ender Ellidokuz, Mehmet Derya Onuk, Cengiz Bolukbas, Erol Avsar, Yuksel Ates, Arzu Tiftikçi, Dinc Dincer, Necip Aytuğ, Sefa Güliter, Cansel Türkay, Ugur Yilmaz, Bulut Yıldırım, Ondokuz Mayıs Üniversitesi, Kırıkkale Üniversitesi, and Maltepe Üniversitesi

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Urea breath test, Lansoprazole, Rapid urease test, Ranitidine bismuth citrate, Ranitidine, Gastroenterology, Drug Administration Schedule, Helicobacter Infections, Young Adult, Clarithromycin, Internal medicine, eradication, Humans, Medicine, Endoscopy, Digestive System, Prospective Studies, Dyspepsia, Aged, biology, medicine.diagnostic_test, Helicobacter pylori, business.industry, Amoxicillin, Proton Pump Inhibitors, Middle Aged, biology.organism_classification, lansoprazole, Anti-Bacterial Agents, Regimen, Treatment Outcome, Histamine H2 Antagonists, Tolerability, Drug Therapy, Combination, Female, business, Bismuth, medicine.drug
Abstract

WOS: 000326481900003, PubMed ID: 24254262, Background/aims: Proton-pump inhibitor- and ranitidine bismuth citrate-based triple regimens are the two recommended first-line treatments for the eradication of Helicobacter pylori. We aimed to compare the effectiveness and tolerability of these two treatments in a prospective, multi-centric, randomized study. Materials and Methods: Patients with dyspeptic complaints were recruited from 15 study centers. Presence of Helicobacter pylori was investigated by both histology and rapid urease test. The patients were randomized to either ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=149) or lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=130) treatment arm for 14 days. Adverse events have been recorded during the treatment phase. A C-13 urea breath test was performed 6 weeks after termination of treatment to assess the efficacy of the therapy. Eradication rate was calculated by intention-to-treat and per-protocol analysis. Results: Two hundred seventy-nine patients (123 male, 156 female) were eligible for randomization. In per-protocol analysis (n=247), Helicobacter pylori was eradicated with ranitidine bismuth citrate- and lansoprazole-based regimens in 74,6% and 69,2% of cases, respectively (p>0,05). Intention-to-treat analysis (n=279) revealed that eradication rates were 65,1% and 63,6% in ranitidine bismuth citrate- and in lansoprazole-based regimens, respectively (p>0,05). Both regimes were well-tolerated, and no serious adverse event was observed during the study. Conclusion: Ranitidine bismuth citrate-based regimen is at least as effective and tolerable as the classical proton-pump inhibitor-based regimen, but none of the therapies could achieve the recommendable eradication rate.

Published
2013

3. Metabolic syndrome frequency in inflammatory bowel diseases

Author

Elif Yorulmaz, Gupse Adali, Hatice Yorulmaz, Celal Ulasoglu, Guralp Tasan, and Ilyas Tuncer

Subjects
Inflammatory bowel disease, insulin resistance, metabolic syndrome, obesity, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background/Aim: Metabolic syndrome (MetS) is a clinical condition characterized by central obesity, elevated triglycerides, low-high density lipoproteins, impaired fasting glucose, and hypertension. There is insufficient data on the prevalence of MetS in patients with inflammatory bowel disease (IBD). This study sought to determine the prevalence of MetS in a Turkish cohort of patients with IBD and the association between insulin resistance (IR) and the MetS parameters, in this population. Patients and Methods: A total of 177 patients over 18 years of age (62 with Crohn′s disease (CD) and 115 with ulcerative colitis (UC)) were enrolled in the study. The presence of at least three criteria of the International Diabetes Federation (IDF) was accepted for the diagnosis of MetS. The Homeostasis Model Assessment (HOMA) was used to determine IR. HOMA values < 1 were considered normal and values > 2.5 indicated a high probability of IR. Results: MetS frequency was higher in patients n=34 (29.5%) with UC than in patients n=11 (17.7%) with CD (P < 0.01). MetS was detected in 12 of the 117 patients (10.3%) with IBD, under 45 years of age, and in 33 of 60 patients (55%) over 45 years of age. HOMA value in n=31 patients (27%) with UC was > 2.5. Body mass index, insulin (P < 0.001), waist circumference, fasting plasma glucose, leukocyte count (P < 0.01), triglycerides, C-reactive protein, and uric acid values (P < 0.05) were significantly higher in UC patients with IR than those without IR. Conclusion: Frequent occurrence of MS with increasing age in IBD, particularly in UC, showed the importance of early diagnosis and treatment of cardiovascular disease risk factors in the long-term follow-up of these diseases.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results